【摘要】 为了研究本单位研制的聚乙二醇化重组人白细胞介素-6(PEG-rhIL-6)在动物体内的药效是否优于未经修饰的重组人白细胞介素-6(rhIL-6)。将健康的雌性BALB/c小鼠分成模型对照组、rhIL-6低、中、高剂量实验组、PEG-rhIL-6低、中、高剂量实验组和空白对照组进行试验,检测小鼠用药前后血小板和体重的动态变化。结果表明PEG-rhIL-6具有减缓环磷酰胺致小鼠血小板减少的作用。高剂量的PEG-rhIL-6与高剂量的rhIL-6相比,减缓血小板减少程度的作用更强(t=2.42,P=0.017),血小板恢复也更快,显示了更好的药效作用。同时PEG-rhIL-6和rhIL-6均可抗环磷酰胺对小鼠体重增长的抑制作用。更多还原

【Abstract】 In order to verify if the PEGylated recombinant human interleukin-6(PEG-rhIL-6) has a better thrombopoietic activity in vivo than that of recombinant human interleukin-6(rhIL-6),healthy female BALB/c mice were divided into eight groups that were negative control,different dose groups for PEG-rhIL-6 and rhIL-6,and blank control respectively.Platelets and body weight of these mice were detected dynamically before and after treatment.The results showed that both PEG-rhIL-6 and rhIL-6 could alleviate the thrombopenia induced by cyclophosphamide,and the high dose of PEG-rhIL-6 is more efficient than that of same dose rhIL-6(t=2.42,P=0.017).At the same time,both PEG-rhIL-6 and rhIL-6 could resist body weight losing induced by inhibition from cyclophosphamide.更多还原